Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients

Bone Marrow Transplantation

Volumn 19, Issue 1, 1997, Pages 23-29

  Palumbo, A ^a   Pileri, A ^a   Triolo, S ^a   Omede P ^a   Bruno, B ^a   Ciravegna, G ^b   Galliano, M ^b   Frieri, R ^b   Boccadoro, M ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b Ospedale Civile   (Italy)

Author keywords

Dose intensive chemotherapy; Hemopoietic progenitor cells; Melphalan; Myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CELL TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MYELOMA; NEUTROPENIA; PRIORITY JOURNAL; REMISSION; STEM CELL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0031031970     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700599     Document Type: Article

References (46)

1. Frei E III, Canellos GP. Dose, a critical factor in cancer chemotherapy. Am J Med 1980; 69: 585-594.
2. Gore ME. Viner C, Meldrum M et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989; 2: 879-885.
3. Barlogie B, Jagannath S, Vesole D, Tricot G. Autologous and allogeneic transplant for multiple myeloma. Semin Hematol 1995; 32: 31-44.
4. Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol 1995; 14: 1786-1799.
5. Socinski MA, Elias A, Schnipper L et al. Granulocyte-macrophage colony stimulating factor expands the circulating hemopoietic progenitor cell compartment in man. Lancet 1988; 339: 640-644.
6. Gianni AM, Bregni M, Stern AC et al. Granulocyte-macrophage stimulating factor to harvest circulating haematopoietic stem cells for autotransplantation. Lancet 1989; 2: 580-585.
7. Tarella C, Boccadoro M, Omedè P et al. Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma. Bone Marrow Transplant 1993; 11: 271-277.
8. Pettengell R, Testa NG, Swindell R et al. Transplantation potential of hemopoietic cells released into circulation during routine chemotherapy for non-Hodgkin's lymphoma. Blood 1993; 82: 2239-2248.
9. Jones HM, Jones SA, Watts MJ et al. Development of a simplified single-apheresis approach for peripheral-blood progenitor cell transplantation in previously treated patients with lymphoma. J Clin Oncol 1994; 12: 1693-1702.
10. Pettengell R. Woll PJ, O'Connor DA et al. Viability of hemopoietic progenitors from whole blood, bone marrow and leukapheresis product: effects of storage media, temperature and time. Bone Marrow Transplant 1994; 14: 703-709.
11. Buzaid AC. Durie BGM. Management of refractory myeloma: a review. J Clin Oncol 1988; 6: 889-905.
12. Boccadoro M, Pileri A. Standard chemotherapy in myelomatosis: an area of great controversy. Hematol Oncol Clin N Am 1992; 6: 371-382.
13. 2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment. Ear J Haematol 1989; 42: 233-237.
14. Barlogie B, Jagannath S, Dixon DO et al. High dose melphalan and granulocyte-macrophage colony stimulating factor for refractory multiple myeloma. Blood 1990; 76: 677-680.
15. Lokhorst HM, Sonneveld P, Whermans PW et al. Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma. Br J Haematol 1996; 92: 44-48.
16. Jagannath S. Vesole DH, Glenn L et al. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992 80: 1666-1672.
17. Harousseau JL, Millipied N, Laporte JP et al. Double-intensive therapy in high risk multiple myeloma. Blood 1992; 79: 2827-2833.
18. Cunningham D, Paz-Ares L, Gore ME et al. High dose melphalan for multiple myeloma: long term follow-up data. J Clin Oncol 1994; 12: 764-768.
19. Anderson KC. Who benefits from high-dose therapy for multiple myeloma? J Clin Oncol 1995; 13: 1291-1296.
20. Attal M, Harousseau JL, Stoppa AM et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Engl J Med 1996; 335: 91-97.
21. Pileri A, Palumbo A, Boccadoro M. Multiple myeloma: a tailored therapy for elderly patients. Hematol Oncol 1993; 11 (Suppl. 1): 67-72.
22. Durie BGM, Salmon SE. Multiple myeloma, macroglobulinemia and monoclonal gammopathies. In: Hoffbrand A, Brown MC, Hirsch J (eds). Recent Advances in Hematology. Churchill Livingstone: New York, 1986, pp 243-255.
23. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842-854.
24. Siena S, Bregni M. Brando B et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77: 400-409.
25. Ogawa M. The role of granulocyte colony-stimulating factor with dose-intensive chemotherapy. Semin Oncol 1994; 21: 7-9.
26. Colton T. Statistics in Medicine. Little Brown: Boston, 1975, p 163.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
28. Pettengell R, Gurney H, Radford JA et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80: 1430-1436.
29. Pettengell R, Penella JW, Thatcher N et al. Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hemopoietic progenitors in whole blood. J Clin Oncol 1995; 13: 148-156.
30. Gianni AM, Tarella C, Bregni M et al. High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J Clin Oncol 1994; 12: 503-509.
31. 2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 691-697.
32. Tepler I, Cannistra SA, Frei E III et al. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. J Clin Oncol 1993; 11: 1583-1591.
33. Freger P, Haferlach T, Eckstein V et al. G-CSF mobilized peripheral blood progenitor cells for allogenic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 1994; 87: 609-613.
34. Ossenkoppele GJ, Jonkhoff AR, Huijgens PC et al. Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma. Bone Marrow Transplant 1994; 13: 37-41.
35. Kinch DC, Knott LJ, Patterson KG et al. Bone marrow processing and cryopreservation. J Clin Pathol 1982; 35: 186-190.
36. Bensinger WI, Rowley SD, Demirer T et al. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol 1996; 14: 1447-1456.
37. Attal M. Harousseau JL, Stoppa AM et al. High dose therapy in multiple myeloma: a prospective randomized study of the 'Intergroupe Francais Du Myeloma' (IFM). Blood 1994; 84: 386a.
38. Jagannath S, Barlogie B, Dicke K et al. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood 1990; 76: 1860-1866.
39. Harousseau JL, Attal M, Divine M et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma. Blood 1995; 85: 3077-3085.
40. Philips GL, Shepherd JD, Barnett MJ et al. Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematological malignancy. J Clin Oncol 1990; 9: 1880-1888.
41. Dimopolous MA, Alexanian R, Przepiorka D et al. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 1993; 82: 2324-2328.
42. Anderson KC, Anderson J, Soiffer R et al. Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood: 1993; 82: 2568-2576.
43. Alexanian R, Dimopolous M, Smith T et al. Limited value of myeloablative therapy for late multiple myeloma. Blood 1994; 83: 512-516.
44. Pileri A, Bernengo MG, Boccadoro M et al. Early recruitment in the human myeloma cell population after cytostatic treatment. Hematologica 1976; 61: 184-193.
45. Karp JE, Humphrey R, Burke PJ. Timed sequential chemotherapy of cytoxan-refractory multiple myeloma with cytoxan and adriamycin based on induced tumor proliferation. Blood 1981; 57: 468-475.
46. Archimbaud E, Thomas X, Leblond V et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol 1995; 13: 11-18.